Liquidia Corporation

NasdaqCM:LQDA

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

United States

Market Cap

USD 1.13 B

Share Price

USD 13.17

Avg Daily Volume

1,539,774

Change (1 day)

-3.45%

Change (1 year)

7.25%

Change (YTD)

11.99%

Liquidia Corporation Enterprise Value to EBITDA (EV/EBITDA) on June 20, 2025: -9.04

Liquidia Corporation Enterprise Value to EBITDA (EV/EBITDA) is -9.04 on June 20, 2025, a -2.18% change year over year. EV/EBITDA ratio compares the enterprise value to the EBITDA; lower suggests more favorable company valuation.

Liquidia Corporation 52-week low Enterprise Value to EBITDA (EV/EBITDA) is -6.20 on June 20, 2025, which is 31.49% above the current Enterprise Value to EBITDA (EV/EBITDA).
Liquidia Corporation 52-week low Enterprise Value to EBITDA (EV/EBITDA) is -13.67 on June 20, 2025, which is -51.18% below the current Enterprise Value to EBITDA (EV/EBITDA).
Liquidia Corporation average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is -8.73.

Daily

From:

To:

Zoom:

Key data

Date	Enterprise Value to EBITDA (EV/EBITDA)	Free Cash Flow Yield	Dividend Yield	Market Capitalization

NasdaqCM: LQDA

Liquidia Corporation

CEO	Dr. Roger A. Jeffs Ph.D.
IPO Date	July 26, 2018
Location	United States
Headquarters	419 Davis Drive
Employees	170
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.